Outcomes Study: Development and Implementation of a Work Productivity and Activity Impairment Assessment Process for Employed Patients with Migraine in a Health-System Specialty Pharmacy Setting

All Posts

Outcomes Study: Development and Implementation of a Work Productivity and Activity Impairment Assessment Process for Employed Patients with Migraine in a Health-System Specialty Pharmacy Setting

Members of our team had the opportunity to present a new poster abstract, "Development and Implementation of a Work Productivity and Activity Impairment Assessment Process for Employed Patients with Migraine in a Health-System Specialty Pharmacy Setting", at the NASP 2025 Annual Meeting & Expo.

 

Authors:

Casey Fitzpatrick, PharmD; Maria Talos, PharmD; Amanda Hickman, PharmD, MPH, MSCS; Hannah Kurtz, PharmD; Christopher Sidun, PharmD; Jedd Schlicht, PharmD; Andrew Wash, PharmD, PhD; Ana Lopez-Medina, PharmD, PhD; Ashley Zupancic, PharmD; Amber Skrtic, PharmD, CSP, AAHIVP; Jessica Mourani, PharmD

 

Background:

  • Employees diagnosed with migraine miss an average of 4.4 workdays each year and have another 11.4 reduced productivity workdays due to migraine attacks.¹ This productivity lost to migraines costs US employers billions of dollars annually.2,3

  • Health-system specialty pharmacy (HSSP) teams support patients in managing migraines through 
    ongoing monitoring of treatment effectiveness and safety, while also ensuring access to medications and promoting long-term adherence.

  • Although HSSP teams are well-positioned to support the clinical management of migraine, the 
    integration of standardized work productivity and impairment assessment tools into routine patient care workflows remains limited.

 

Objectives:

  • To describe a work productivity and activity impairment assessment process for employed patients with migraine in an HSSP setting.

 

Read about the team's findings by downloading the outcomes study below.

 

1 Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the impact on people's life. J Headache Pain. 2019;20 (1):41. doi:10.1186/slO 194-019-0993-0


2 Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159(8):813-818. doi:10.1001/archinte.159.8.813


3 Hawkins K, WangS, Rupnow MF. Indirect cost burden of migraine in the United States. J Occup Environ Med. 2007;49 (4):368-37 4. doi:10.1097/ JOM.Ob013e31803b9510

 

 

Submit your contact information below to receive insights from our team of pharmacy solutions experts.